Soleno Therapeutics (NASDAQ:SLNO) Downgraded to “Hold” Rating by Piper Sandler

Soleno Therapeutics (NASDAQ:SLNO) was downgraded by equities researchers at Piper Sandler from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

SLNO has been the subject of several other reports. Lifesci Capital downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. Wells Fargo & Company dropped their price target on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Oppenheimer dropped their price target on Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 18th. HC Wainwright dropped their target price on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, March 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Soleno Therapeutics has an average rating of “Hold” and an average target price of $93.90.

Soleno Therapeutics Trading Up 0.2%

Shares of NASDAQ SLNO opened at $52.35 on Tuesday. Soleno Therapeutics has a 12 month low of $29.43 and a 12 month high of $90.32. The company has a market cap of $2.70 billion, a price-to-earnings ratio of 227.62 and a beta of -2.81. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The business has a fifty day simple moving average of $38.17 and a 200-day simple moving average of $47.80.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analysts’ expectations of $88.55 million. Sell-side analysts predict that Soleno Therapeutics will post -3.72 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SLNO. Janus Henderson Group PLC boosted its position in shares of Soleno Therapeutics by 18.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock worth $332,302,000 after purchasing an additional 1,122,015 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Soleno Therapeutics by 43.7% in the 4th quarter. Wellington Management Group LLP now owns 3,322,799 shares of the company’s stock worth $153,846,000 after purchasing an additional 1,010,704 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Soleno Therapeutics by 9.0% in the 4th quarter. Vanguard Group Inc. now owns 3,060,361 shares of the company’s stock worth $141,695,000 after purchasing an additional 253,212 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Soleno Therapeutics by 12.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock worth $134,270,000 after purchasing an additional 322,223 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Soleno Therapeutics by 21.9% in the fourth quarter. State Street Corp now owns 2,649,626 shares of the company’s stock valued at $122,678,000 after purchasing an additional 476,590 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine agreed to acquire Soleno for about $2.9B, offering $53.00 per share in cash (a meaningful premium to recent trade); the deal provides a near‑term liquidity event and floor for shareholder value. Neurocrine to Buy Soleno for $2.9 Billion
• Positive Sentiment: Market commentary and coverage noted the $53/share offer and framed it as a strategic fit for Neurocrine’s rare‑disease/endocrinology push, supporting near‑term upside to the transaction price if the deal closes. Neurocrine Biosciences to acquire Soleno Therapeutics
• Neutral Sentiment: Soleno voluntarily withdrew its European marketing application for its Prader‑Willi treatment as Neurocrine sharpens focus on the U.S. market — a programmatic change that reduces near‑term EU regulatory exposure but removes a potential international revenue opportunity. Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover
• Negative Sentiment: Several sell‑side firms downgraded or cut price targets (Cantor Fitzgerald, Wolfe Research, Lifesci; TD Cowen cut its target to $53 from $85) — analyst caution could pressure sentiment and constrain upside beyond the deal price. Cantor Fitzgerald Downgrades Soleno Therapeutics
• Negative Sentiment: Multiple securities class‑action lawsuits, and a flurry of law‑firm notices seeking lead plaintiffs, allege disclosures issues tied to the DCCR (VYKAT XR) program; several firms are investigating the fairness of the Neurocrine deal and potential fiduciary claims — these legal risks can create deal uncertainty, potential remediation costs, and timeline delays. Soleno Therapeutics, Inc. (SLNO) Class Action Lawsuit
• Negative Sentiment: Investor‑rights and M&A litigation firms have launched investigations into whether Soleno’s board obtained a fair price and whether prior disclosures misstated drug risks — these actions raise the chance of post‑deal litigation or negotiated adjustments. Halper Sadeh investigation into sale price

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.